Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Rare Kidney Diseases Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for rare kidney diseases has experienced robust expansion over the past few years. Projections indicate an increase from $3.03 billion in 2025 to $3.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.5%. This historical growth has been driven by factors such as the scarcity of treatment options for uncommon renal conditions, heightened awareness surrounding genetic kidney disorders, a rise in autoimmune-related nephropathy cases, the proliferation of specialized nephrology care facilities, and the early integration of immunosuppressive treatments into clinical practice.
The market for rare kidney diseases is anticipated to experience substantial expansion in the coming years. By 2030, its value is projected to reach $4.88 billion, driven by a compound annual growth rate (CAGR) of 10.2%. This forecasted growth is fueled by progress in genomics-driven drug discovery, a higher number of orphan drug approvals, greater investment in research on rare conditions, the increasing application of personalized medicine, and an expanding arsenal of complement and immune-focused therapies. Key trends shaping this period include a stronger emphasis on targeted treatments for uncommon renal disorders, a surge in clinical trials dedicated to orphan kidney medications, the widening use of biologics for immune-mediated kidney ailments, the development of companion diagnostics for early identification of diseases, and enhanced regulatory incentives designed to support the development of therapies for rare diseases.
Download A Free Sample Report For Comprehensive Market Insights:
Rare Kidney Diseases Market Expansion Drivers: What Is Shaping Future Growth?
The growing occurrence of chronic kidney disease (CKD) is playing a major role in advancing the rare kidney disease market. This condition involves kidney damage that hinders their ability to properly filter blood. As the prevalence of chronic kidney disease rises, the likelihood of patients developing rare kidney diseases also increases, thereby boosting the demand for therapies tailored to these conditions. For example, as reported in August 2025 by the National Kidney Foundation, Inc.—a non-profit health organization based in the United States—the Senate granted a $5 million increase in the FY 2026 Labor, Health and Human Services, and Education appropriations bill, aimed at improving kidney transplant reform and early detection. This addition raises the total funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative to $59 million. Consequently, the heightened prevalence of chronic kidney disease (CKD) is expected to propel growth in the rare kidney disease market.
Rare Kidney Diseases Market Segment Analysis Highlighting Growth Areas
The rare kidney diseases market covered in this report is segmented –
1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications
2) By Type Of Molecule: Small Molecules, Biologics
3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration
Subsegments:
1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management
2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics
3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents
4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies
5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies
6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders
Rare Kidney Diseases Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Key players in the rare kidney diseases market are concentrating their efforts on creating non-immunosuppressive treatments specifically for these conditions. This type of therapy offers a distinct approach that addresses progressive kidney diseases, something conventional treatments for rare kidney disorders are unable to achieve. A notable example occurred in February 2023 when Travere Therapeutics, a biopharmaceutical firm based in the United States, introduced sparsentan under the brand name Filspari. This drug represents the first non-immunosuppressive therapy to receive approval for primary immunoglobulin A nephropathy (IgAN). Through its unique mechanism, Filspari works by blocking both angiotensin and endothelin receptors, giving it a clear advantage over standard ACE inhibitors and ARBs—those commonly used antihypertensive drugs that have been adapted for IgAN management only because they lower renal blood pressure.
Rare Kidney Diseases Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the rare kidney diseases market are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc.
Access The Complete Rare Kidney Diseases Market Report:
Rare Kidney Diseases Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the leading region in the rare kidney disease market in 2025. The regions covered in the rare kidney diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model